Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: Current evidence and future perspectives

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 556-562

  Sehouli, J ^a   Alfaro, V ^b   Gonzlez martn A ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHARMAMAR S A   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Ovarian cancer; Platinum free interval; Recurrence; Trabectedin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN;

ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CARDIOTOXICITY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; METASTATIC BREAST CANCER; MONOTHERAPY; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DIOXOLES; DOXORUBICIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TETRAHYDROISOQUINOLINES;

EID: 84857594981     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr321     Document Type: Review

References (50)

1. Gadducci A, Tana R, Teti G et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18: 615-620.
2. Monk BJ. Recurrent ovarian cancer Exploring options for patients who relapse 6 to 12 months after chemotherapy. Oncology Biotech & News (HCP Beta Live) 2010. Priority report: 1-6.
3. Kaye S. Management of partially platinum-sensitive relapsed ovarian cancer. Eur J Cancer Suppl 2008; 6: 16-21.
4. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-653.
5. Ledermann JA, Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006; 5: 341-354.
6. Pujade-Lauraine E, Vergote I, Pignata S, Kristensen G. Optimizing management of recurrent epithelial ovarian cancer with non-platinum-based chemotherapy. Clin Ovarian Cancer 2008; 1: 139-140.
7. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007; 64: 129-138.
8. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinumsensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009; 19 (Suppl 2): S63-S67.
9. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999; 4: 87-94.
10. McClelland SE, Burrell RA, Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 2009; 8: 3262-3266.
11. Horowitz NS, Hua J, Gibb RK et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004; 94: 67-73.
12. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209-216.
13. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-1588.
14. Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6: 5.
15. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263-268.
16. Power P, Stuart G, Oza A et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 2009; 114: 410-414.
17. Rapoport BL, Vorobiof DA, Slabber C et al. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinumsensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009; 19: 1137-1141.
18. Weber B, Lortholary A, Mayer F et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009; 29: 4195-4200.
19. Mirza MR, Lund B, Lindegaard JC et al. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2010; 119: 26-31.
20. Ferrero A, Logrippo V, Spanu PG et al. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer 2009; 19: 1529-1534.
21. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
22. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
23. Vasey P, Largillier R, Gropp M et al. 18LBA. A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients. Eur J Cancer Suppl 2009; 7: 11.
24. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
25. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinumsensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22: 39-48.
26. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006; 33: S12-S16.
27. Meier W, Lichtenegger W, Marth C et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICOGCIG Intergroup Study (HECTOR). J Clin Oncol 2010; 28: (Abstr 5071).
28. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 26: 3176-3182.
29. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-1874.
30. Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinumbased regimens. Br J Cancer 2007; 97: 1618-1624.
31. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-1802.
32. Kaye SB, Colombo N, Monk BJ et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011; 22: 49-58.
33. Pignata S, Ferrandina G, Scarfone G et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 2006; 71: 320-326.
34. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20-28.
35. Pignata S, Pujade-Lauraine E, du Bois A, Pisano C. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 2010; 73: 23-30.
36. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9: 2157-2163.
37. Schoffski P, Taron M, Jimeno J et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin. Eur J Cancer 2011; 47: 1006-1012.
38. Schöffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). Proc Am Soc Clin Oncol 2006;; 2006. ASCO Annual Meeting Proceedings Part I, vol. 24, no. 18S (June 20 Supplement): 9522.
39. Tedesco KL, Blum JL, Goncalves A et al. A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line mutated metastatic breast cancer (MBC). J Clin Oncol 2010; 28: 123. (Abstr 1038).
40. Mandola MV, Kolb EA, Scotto KW. Poly (ADP-ribose) polymerase (PARP) contributes to cellular sensitivity to trabectedin (Yondelis™). Proc Am Assoc Cancer Res 2005; 46: 972. (Abstr 4122).
41. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
42. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 2964-2971.
43. Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235-2244.
44. Sessa C, D'Incalci M. Trabectedin in ovarian cancer: could we expect more? Ann Oncol 2011; 22: 7-8.
45. Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol 2005; 98: 403-408.
46. Markman M, Lewis JL Jr, Saigo P et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1993; 71: 634-637.
47. Moore KN, Reid MS, Fong DN et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 2008; 110: 133-139.
48. Demetri G, Blay JY, Yovine A et al. Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. Ann Oncol 2009; 7: 590-591; (Abstr O9402).
49. Lebedinsky C, Gómez J, Park YC et al. Trabectedin has a low cardiac risk profile: a comprehensive safety analysis. Ann Oncol 2010; 21 (Suppl 28): 21. viii308 (Abstr 984P).
50. Vergote I, Vermorken J, Pujade Lauraine E et al. Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. Eur J Caner Suppl 2009; 7: 458. (Abstr P8028).